Message Font: Serif | Sans-Serif
 
No. of Recommendations: 0
goruck,

Excellent post. You hit all the key reasons why it is hard to predict what the market for this drug will be. Until phase III trials are completed and we get some sense for how it stacks up against competing therapies it becomes anyones guess. The 30,000 potential new customers per year are just that, potential. That would be my upper limit for sales. The lower limit conservatively (if the drug is actually efficacious) may be only 5 to 10% of that if its only indicated for metastatic disease unresponsive to other measures. Meanwhile there is still Epogen to keep the company going.

-MV
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Community Home
Speak Your Mind, Start Your Blog, Rate Your Stocks

Community Team Fools - who are those TMF's?
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.
Advertisement